Runx2 in normal tissues and cancer cells: A developing story.
The Runx transcription factors are essential for mammalian development, most notably in the haematopoietic and osteogenic lineages. Runx1 and its binding partner, CBFbeta, are frequently targeted in acute leukaemia but evidence is accumulating that all three Runx genes may have a role to play in a wider range of cancers, either as tumour promoters or tumour suppressors. Whilst Runx2 is renowned for its role as a master regulator of bone development we discuss here its expression pattern and putative functions beyond this lineage. Furthermore, we review the evidence that RUNX2 promotes neoplastic development in haematopoietic lineages and in advanced mammary and prostate cancer.
Blyth
Karen
K
Beatson Institute for Cancer Research, Bearsden, Glasgow, UK. K.Blyth@beatson.gla.ac.uk
Vaillant
Francois
F
Jenkins
Alma
A
McDonald
Laura
L
Pringle
Marie Anne
MA
Huser
Camille
C
Stein
Torsten
T
Neil
James
J
Cameron
Ewan R
ER
D000818:Animals; D050659:Core Binding Factor Alpha 1 Subunit / Q000378:metabolism*; D050658:Core Binding Factor beta Subunit / Q000378:metabolism*; D016147:Genes, Tumor Suppressor; D019337:Hematologic Neoplasms / Q000378:metabolism*; D006801:Humans; D051379:Mice; D009362:Neoplasm Metastasis / Q000235:genetics; D009375:Neoplasms, Glandular and Epithelial / Q000378:metabolism*; D009857:Oncogenes
D050659:Core Binding Factor Alpha 1 Subunit; D050658:Core Binding Factor beta Subunit; C493716:Runx2 protein, mouse